While NKG2D.CAR-NK cells demonstrated in vitro anti-AML cytotoxicity, the simultaneous ectopic production of hIL15 and three CAR-NK injections was necessary for sustaining the in vivo persistence and augmenting the in vivo anti-AML efficacy of NKG2D.CAR-NK cells [75]. This evidence concerns the gene KLRK1 and acute myeloid leukemia.